FEMASYS INC (FEMY): Price and Financial Metrics Recent IPO
GET POWR RATINGS... FREE!
FEMY Stock Price Chart Interactive Chart >
FEMY Price/Volume Stats
|Current price||$6.52||52-week high||$13.75|
|Prev. close||$6.77||52-week low||$6.50|
|Day high||$6.99||Avg. volume||144,886|
|50-day MA||$7.32||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||76.94M|
FEMASYS INC (FEMY) Company Bio
Femasys Inc., a biomedical company, researches, develops, and manufactures medical devices for the women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a sterile, single-use disposable endocervical curettage product; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
Most Popular Stories View All
FEMY Latest News Stream
|Loading, please wait...|
FEMY Latest Social Stream
View Full FEMY Social Stream
Latest FEMY News From Around the Web
Below are the latest news stories about Femasys Inc that investors may wish to consider to help them evaluate FEMY as an investment opportunity.
ATLANTA, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (“Femasys” or the “Company”), a biomedical company developing a suite of product candidates to transform women’s healthcare with minimally invasive, non-surgical, in-office technologies, announced that the Company has been added to the Russell Microcap® Index today when the U.S. market opened. The Russell Microcap Index is widely used by investment managers and institutional investors for index funds and as benchmarks for ac
In the last year, multiple insiders have substantially increased their holdings of Femasys Inc. ( NASDAQ:FEMY ) stock...
-- Industry veteran with over than two decades of experience in medical affairs to lead clinical and medical affairs at Femasys -- ATLANTA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company developing a suite of product candidates to transform women’s healthcare with minimally invasive, non-surgical, in-office technologies, today announced the appointment of Edward G. Evantash, M.D., as chief medical officer. Dr. Evantash brings over two decades of industry exp
Completed initial public offering (“IPO”) raising net proceeds of $31.6 million Appointed Anne Morrissey to the Board of Directors, an industry expert with decades of medical device experience Initiated 792-patient, pivotal LOCAL trial after receipt of investigational device exemption (IDE) submission approval for FemaSeed™ ATLANTA, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company developing a suite of product candidates to transform women’s healthcare with min
First in Class Insemination Treatment for Infertility LOCAL Pivotal Trial to Enroll Up to 792 Patients Across 20 U.S. Centers ATLANTA, July 20, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on transforming women's healthcare, today announced the initiation and first patient treated in a pivotal trial evaluating FemaSeed, a first in class, localized directional insemination product candidate for infertility. “For more than 20 years, current approaches to infer
FEMY Price Returns